Literature DB >> 23322442

Molecular defects in Moroccan patients with ataxia-telangiectasia.

L Jeddane1, F Ailal, C Dubois-d'Enghien, O Abidi, I Benhsaien, A Kili, S Chaouki, Y Kriouile, N El Hafidi, H Fadil, R Abilkassem, N Rada, A A Bousfiha, A Barakat, D Stoppa-Lyonnet, H Bellaoui.   

Abstract

Ataxia-telangiectasia (AT) is a rare autosomal recessive disease, affecting neurologic and immune system. Numerous mutations are described in the ATM gene in several populations. However, in Morocco, few data are available concerning this condition. Our main goal is to determine clinical, immunological, and molecular presentation of Moroccan patients with AT. We screened 27 patients, out of 22 unrelated families, for ATM gene mutations. All our patients showed ataxia, ocular telangiectasia, and immunodeficiency, as well as elevated serum alphafetoprotein levels. Mean age at diagnosis was 5.51 years, and consanguinity rate was 81.8 %. Mean age at onset was 2.02 years, and mean time to diagnosis was 3.68 years. We found 14 different mutations in 19 unrelated families, of which 7 were not reported. Our results showed that c.5644C>T mutation was the most common in our series. However, further studies are required to demonstrate a founder effects on ATM gene in Moroccan patients, who showed mutational heterogeneity otherwise. Our data indicate that direct sequencing of coding exons is sufficient for a high detection rate in ATM in Moroccan population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23322442     DOI: 10.1007/s12017-013-8218-1

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  37 in total

1.  Five haplotypes account for fifty-five percent of ATM mutations in Brazilian patients with ataxia telangiectasia: seven new mutations.

Authors:  Gabriela Coutinho; Midori Mitui; Catarina Campbell; Beatriz T Costa Carvalho; Shareef Nahas; Xia Sun; Yong Huo; Chih-Hung Lai; Yvonne Thorstenson; Robert Tanouye; Salmo Raskin; Chong A Kim; Juan Llerena; Richard A Gatti
Journal:  Am J Med Genet A       Date:  2004-04-01       Impact factor: 2.802

2.  Ataxia telangiectasia: the consequences of a delayed diagnosis.

Authors:  Caroline M P W Mandigers; Bart P C van de Warrenburg; Luc J A Strobbe; Irma Kluijt; Andre H M Molenaar; Dominic A X Schinagl
Journal:  Radiother Oncol       Date:  2011-02-26       Impact factor: 6.280

3.  Ataxia-telangiectasia: founder effect among north African Jews.

Authors:  S Gilad; A Bar-Shira; R Harnik; D Shkedy; Y Ziv; R Khosravi; K Brown; L Vanagaite; G Xu; M Frydman; M F Lavin; D Hill; D A Tagle; Y Shiloh
Journal:  Hum Mol Genet       Date:  1996-12       Impact factor: 6.150

4.  Importance of ATM gene as a susceptible trait: predisposition role of D1853N polymorphism in breast cancer.

Authors:  Parvin Mehdipour; Marzieh Mahdavi; Javad Mohammadi-Asl; Morteza Atri
Journal:  Med Oncol       Date:  2010-04-16       Impact factor: 3.064

5.  Unusual and severe disease course in a child with ataxia-telangiectasia.

Authors:  Isabelle Meyts; Corry Weemaes; Chris De Wolf-Peeters; Marijke Proesmans; Marleen Renard; An Uyttebroeck; Kris De Boeck
Journal:  Pediatr Allergy Immunol       Date:  2003-08       Impact factor: 6.377

Review 6.  Ataxia-telangiectasia: an overview.

Authors:  E Boder
Journal:  Kroc Found Ser       Date:  1985

7.  Independent mutational events are rare in the ATM gene: haplotype prescreening enhances mutation detection rate.

Authors:  Midori Mitui; Catarina Campbell; Gabriela Coutinho; Xia Sun; Chih-Hung Lai; Yvonne Thorstenson; Sergi Castellvi-Bel; Luis Fernandez; Eugenia Monros; Beatriz Tavares Costa Carvalho; Oscar Porras; Gumersindo Fontan; Richard A Gatti
Journal:  Hum Mutat       Date:  2003-07       Impact factor: 4.878

8.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase.

Authors:  K Savitsky; A Bar-Shira; S Gilad; G Rotman; Y Ziv; L Vanagaite; D A Tagle; S Smith; T Uziel; S Sfez; M Ashkenazi; I Pecker; M Frydman; R Harnik; S R Patanjali; A Simmons; G A Clines; A Sartiel; R A Gatti; L Chessa; O Sanal; M F Lavin; N G Jaspers; A M Taylor; C F Arlett; T Miki; S M Weissman; M Lovett; F S Collins; Y Shiloh
Journal:  Science       Date:  1995-06-23       Impact factor: 47.728

9.  Identification of two mutations for ataxia telangiectasia among the Druze community.

Authors:  Fuad Fares; Sivan Axelord Ran; Miriam David; Nathanel Zelnik; Yehudah Hecht; Hasan Khairaldeen; Aaron Lerner
Journal:  Prenat Diagn       Date:  2004-05       Impact factor: 3.050

10.  Predominance of null mutations in ataxia-telangiectasia.

Authors:  S Gilad; R Khosravi; D Shkedy; T Uziel; Y Ziv; K Savitsky; G Rotman; S Smith; L Chessa; T J Jorgensen; R Harnik; M Frydman; O Sanal; S Portnoi; Z Goldwicz; N G Jaspers; R A Gatti; G Lenoir; M F Lavin; K Tatsumi; R D Wegner; Y Shiloh; A Bar-Shira
Journal:  Hum Mol Genet       Date:  1996-04       Impact factor: 6.150

View more
  5 in total

1.  First report on the Moroccan registry of primary immunodeficiencies: 15 years of experience (1998-2012).

Authors:  A A Bousfiha; L Jeddane; N El Hafidi; N Benajiba; N Rada; J El Bakkouri; A Kili; S Benmiloud; I Benhsaien; I Faiz; O Maataoui; Z Aadam; A Aglaguel; L Ait Baba; Z Jouhadi; R Abilkassem; M Bouskraoui; M Hida; J Najib; H Salih Alj; F Ailal
Journal:  J Clin Immunol       Date:  2014-03-12       Impact factor: 8.317

Review 2.  Neurogenomics in Africa: Perspectives, progress, possibilities and priorities.

Authors:  Rufus O Akinyemi; Mayowa O Owolabi; Tolulope Oyeniyi; Bruce Ovbiagele; Donna K Arnett; Hemant K Tiwari; Richard Walker; Adesola Ogunniyi; Raj N Kalaria
Journal:  J Neurol Sci       Date:  2016-05-06       Impact factor: 3.181

3.  Ataxia-telangiectasia with a novel ATM gene mutation and Burkitt leukemia: A case report.

Authors:  Fanghua Ye; Wenwen Chai; Minghua Yang; Min Xie; Liangchun Yang
Journal:  Mol Clin Oncol       Date:  2018-09-17

4.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

Review 5.  Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders.

Authors:  Agata Pastorczak; Andishe Attarbaschi; Simon Bomken; Arndt Borkhardt; Jutte van der Werff Ten Bosch; Sarah Elitzur; Andrew R Gennery; Eva Hlavackova; Arpád Kerekes; Zdenka Křenová; Wojciech Mlynarski; Tomasz Szczepanski; Tessa Wassenberg; Jan Loeffen
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.